Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 2 Interventional Results available

RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome

NCT00621855
View directory record Official record
Conditions
Coronary Disease
Interventions
placebo, dabigatran etexilate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,878 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT03820726
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

NCT00926289
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan, Hydrochlorothiazide
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 10, 2026, 2:42 PM EDT
Recruiting Phase 1 Interventional

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

NCT05916313
View directory record Official record
Conditions
Glioma
Interventions
BI 764532
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Orange, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Active, not recruiting Phase 1 Interventional

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

NCT06132113
View directory record Official record
Conditions
Neuroendocrine Neoplasms
Interventions
BI 764532, Carboplatin, Etoposide, Cisplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder

NCT00105989
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Newport Beach, California • Sherman Oaks, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
BI 10773, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Plantation, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 10, 2026, 2:42 PM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 2 Interventional

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

NCT05512377
View directory record Official record
Conditions
Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Interventions
brigimadlin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy People to Test How 2 Different Formulations of BI 695501 Are Taken up by the Body When Given as an Injection

NCT05203289
View directory record Official record
Conditions
Healthy
Interventions
BI 695501 - higher concentration, BI 695501 - lower concentration
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

NCT03594110
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Empagliflozin, Matching placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
47
States / cities
Huntsville, Alabama • Mesa, Arizona • San Diego, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT06066515
View directory record Official record
Conditions
Obesity
Interventions
survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Terminated Phase 2 Interventional Results available

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

NCT02240706
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Best Supportive Care, BI 836858
Procedure · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Jacksonville, Florida • Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

NCT02788474
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
nintedanib, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Jasper, Alabama • Danbury, Connecticut • Clearwater, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

NCT05734690
View directory record Official record
Conditions
Heart Failure
Interventions
SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Not applicable Interventional

Exploratory Study of a Digital Therapeutics in People With Schizophrenia

NCT05438160
View directory record Official record
Conditions
Schizophrenia
Interventions
Clinical Learning Study smartphone app (i.e., the study app)
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Anaheim, California • Torrance, California • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 10, 2026, 2:42 PM EDT
Completed No phase listed Observational Results available

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

NCT02043808
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
25,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2015 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 4 Interventional

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

NCT00034840
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan, valsartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 2 Interventional Results available

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

NCT01522768
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Afatinib and Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 1 Interventional

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

NCT03165227
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
BI 685509, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Huntsville, Alabama • La Mesa, California • Los Gatos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 4 Interventional Results available

Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism

NCT01976507
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
dabigatran etexilate mesylate
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 10, 2026, 2:42 PM EDT
Terminated Phase 4 Interventional Results available

Acute Cough Study In Children

NCT01257542
View directory record Official record
Conditions
Common Cold, Infections, Upper Respiratory Tract
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

NCT00808067
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dabigatran dose 1, dabigatran dose 2
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
5,897 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
216
States / cities
Birmingham, Alabama • Mobile, Alabama • Lake Havasu City, Arizona + 185 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 10, 2026, 2:42 PM EDT
Completed Phase 3 Interventional Results available

12 / 48 wk Pivotal PFT vs PBO in COPD II

NCT00782509
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI 1744), Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
28
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Waterbury, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 10, 2026, 2:42 PM EDT